News | July 10, 2022
Sirio Pharma announces agreement to acquire best formulations
The combined company will be able to better serve both our global and regional customers with local production
The combined company will be able to better serve both our global and regional customers with local production
AbTis will have access to WuXi XDC's integrated services for linker and payload manufacturing
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
The acquisition continues the growth and expansion course of the ALPLApharma business division established in 2019
This GMP and Pre-Approval Inspection is part of the routine business operations and the company shall submit to US FDA within the stipulated timeline
The US FDA has determined that the inspection classification of the facility is Voluntary Action Indicated
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
Site Enhances New Modality CRDMO Platform Capacity for Customers
The new facility will be delivered through an investment of approximately CHF 500 million and is expected to be completed in 2026
Subscribe To Our Newsletter & Stay Updated
